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Dasatinib, a second-generation BCR-ABL1 tyrosine kinaseinhibitor, is approved for the treatment of chronic myeloidleukemia and Philadelphia chromosome-positive acute lym-
phoblastic leukemia, both as first-line therapy and after imatinib intoler-
ance or resistance. While generally well tolerated, dasatinib has been
associated with a higher risk for pleural effusions. Frequency, risk fac-
tors, and outcomes associated with pleural effusion were assessed in
two phase 3 trials (DASISION and 034/Dose-optimization) and a pooled
population of 11 trials that evaluated patients with chronic myeloid
leukemia and Philadelphia chromosome-positive acute lymphoblastic
leukemia treated with dasatinib (including DASISION and 034/Dose-
optimization). In this largest assessment of patients across the dasatinib
clinical trial program (N=2712), pleural effusion developed in 6-9% of
patients at risk annually in DASISION, and in 5-15% of patients at risk
annually in 034/Dose-optimization. With a minimum follow up of 5 and
7 years, drug-related pleural effusion occurred in 28% of patients in
DASISION and in 33% of patients in 034/Dose-optimization, respec-
tively. A significant risk factor identified for developing pleural effusion
by a multivariate analysis was age. We found that overall responses to
dasatinib, progression-free survival, and overall survival were similar in
patients who developed pleural effusion and in patients who did not.
clinicaltrials.gov identifier 00481247; 00123474.
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ABSTRACT
Introduction
Dasatinib is a potent second-generation BCR-ABL1 tyrosine kinase inhibitor
(TKI) approved at 100 mg once daily (QD) as first-line therapy in patients with
chronic myeloid leukemia in chronic phase (CML-CP), and in patients with CML-
CP who are resistant to or intolerant of prior therapy.1 Dasatinib is also approved
at 140 mg QD in patients with accelerated or blast phase CML (CML-AP/BP) or
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with
resistance to or intolerance of prior therapy.2-4 
Although fluid retention has been associated with TKIs used to treat CML, pleu-
ral effusions, specifically with exudate characteristics, have been reported more
commonly with dasatinib.1,5,6 The exact mechanisms behind treatment-related pleu-
ral effusion remain to be elucidated; however, it has been suggested that immune
mechanisms may play a role, based on reports of association with lymphocytosis
and the presence of lymphocyte-dominant exudates and chyle accumulate.7-9
Alternatively, pleural effusion (with or without exudates) may also occur through
inhibition of platelet-derived growth factor receptor-β or SRC-family kinases.10,11 In
Ferrata Storti Foundation
clinical practice, pleural effusion observed with dasatinib
therapy remains a concern for both patients and pre-
scribers. 
Risk factors for pleural effusion in dasatinib-treated
patients have been described in previous reports, including
advanced age, advanced disease, heart disease, preexisting
hypertension, hypercholesterolemia, autoimmune disease,
rash, drug dose and schedule, and the presence of lympho-
cytosis.10,12-14 A correlation with plasma trough level, drug
exposure, treatment duration, and depth of response to
treatment has been suggested, but not confirmed.15
Here, we present an analysis of the proportion of
patients with pleural effusion by grade, and efficacy out-
comes in these patients, in dasatinib clinical trials.
Additionally, we report the results of multivariate analyses
of dasatinib clinical trial data, exploring factors associated
with the development of pleural effusion in dasatinib-
treated patients.
Methods
Patient populations
DASISION (CA180-056). In the phase 3 dasatinib versus ima-
tinib study in treatment-naive CML patients (DASISION [CA180-
056]; clinicaltrials.gov identifier 00481247), 519 patients with newly
diagnosed CML-CP were randomized to receive either 100 mg
QD dasatinib (n=259) or 400 mg QD imatinib (n=260).16-18 The pri-
mary endpoint was the proportion of patients with confirmed
complete cytogenetic responses (CCyR) by 12 months. Patients
included in this report had a minimum of 5 years of follow up.19 
034/Dose-optimization (CA180-034). In the phase 3 dose-optimiza-
tion study in imatinib-resistant or -intolerant CML-CP patients
(CA180-034; clinicaltrials.gov identifier 00123474), 670 patients with
CML-CP intolerant of or resistant to imatinib were randomized to
receive dasatinib 100 mg QD (n=167), 140 mg QD (n=167), 50 mg
twice daily (BID; n=168), or 70 mg BID (n=168).20-22 A subset of
patients modified their dose over the course of the study; howev-
er, analyses of data were performed according to each patient’s ini-
tial randomization. The primary endpoint was the percentage of
patients with major cytogenetic response (MCyR) after a mini-
mum follow up of 6 months. Patients included in this report had
a minimum of 7 years of follow up.23
Pooled population of patients with Ph+ leukemia. Patients (N=2712)
with Ph+ leukemia who were treated with first- or second-line
dasatinib 15 mg to 240 mg QD in 1 of 11 phase 1, 2, or 3 trials
were included in these analyses (Online Supplementary Table
S1).16,19,21,23-31 DASISION and 034/Dose-optimization were ana-
lyzed separately and as part of the pooled population for this
report. In total, 324 newly diagnosed patients treated with dasa-
tinib 100 mg QD (DASISION [n=258], CA180-363 [n=66]), and
2388 patients with CML (CML-CP [n=1294], advanced phases of
CML [n=958]) or Ph+ ALL (n=136) previously treated with ima-
tinib were included. Previously treated patients received dasatinib
at daily doses ranging from 15 mg to 240 mg administered once or
in divided doses daily.   
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Table 1. Summary of pleural effusion events in dasatinib-treated patients with CML-CP in DASISION and 034/Dose-optimization.
Dasatinib-treated patients, n (%)
DASISION 034/Dose-optimization
(n=258) (n=662)
Patients with PE (any grade), n (%) 74 (29) 227 (34)
Patients with drug-related PE (any grade), n (%) 73 (28) 220 (33)
Grade 1 21 (8) 28 (4)
Grade 2 45 (17) 144 (22)
Grade 3 7 (3) 44 (7)
Grade 4 0 4 (1)
Patients with >1 drug-related PE (any grade), n (%) 45 (17) 134 (20)
Median time to first drug-related PE (any grade), weeks (range) 114 (4-299) 60 (1-371)
Grade 1 132 (4-299) 60 (2-369)
Grade 2 114 (6-281) 83 (1-371)
Grade 3 175 (114-274) 105 (3-350)
Median duration of first drug-related PE (any grade), weeks (range) 4 (0-223) 4 (0-235)
Grade 1 7 (1-223) 7 (0-80)
Grade 2 3 (1-210) 3 (0-235)
Grade 3 4 (0-25) 3 (0-96)
First occurrences of PE (any grade) by patients at risk, n/n at risk (%)*
Year 1 20/258 (8) 100/662 (15)
Year 2 13/209 (6) 37/430 (9)
Year 3 11/184 (6) 30/305 (10)
Year 4 14/160 (9) 15/230 (7)
Year 5 12/141 (9) 17/182 (9)
Year 6 NA 7/144 (5)
Year 7 NA 9/133 (7)
*Two patients in 034/Dose-optimization have not been categorized into any year due to missing PE onset date. CML-CP: chronic myeloid leukemia in chronic phase; NA: not
applicable; PE: pleural effusion.
Assessments
Pleural effusions were monitored continuously in treated
patients who received at least 1 dose of study drug (DASISION
[n=258], 034/Dose-optimization [n=662], pooled population
[n=2712]). Pleural effusion by first onset is presented by year for
patients at risk (the number of patients who were treated within
a year and did not have pleural effusion). Effusions were graded
according to the Common Terminology Criteria for Adverse
Pleural effusion in dasatinib-treated CML patients
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Figure 1. Retrospective multivariate analysis to determine if there was an association between pleural effusion and potential risk factors. Odds ratios (ORs) with
95% confidence intervals (CIs) are shown for potential predictive variables listed for patients with CML-CP treated with 100 mg QD dasatinib from DASISION (A),
034/Dose-optimization (B), or both DASISION and 034/Dose-optimization (C). AFRI: Africa; CA: Caribbean; CML-CP: chronic myeloid leukemia in chronic phase; EU:
European Union; MMR: major molecular response, BCR-ABL1 transcripts ≤0.1% on the International Scale (IS) corresponding to a 3-log reduction from a standardized
baseline; MR4: BCR-ABL1 transcripts <0.01% (IS) corresponding to a 4-log reduction from a standardized baseline; MR4.5: BCR-ABL1 transcripts ≤0.0032% (IS) cor-
responding to a 4.5-log reduction from a standardized baseline; NA: North America; PE: pleural effusion; QD: once daily.
A
B
C
Events Version 3.032 in DASISION and 034/Dose-optimization.
Additional description of assessments and statistical analyses can
be found in the Online Supplementary Material.
Each study protocol was approved by all institutional review
boards, ethics committees, and national competent authorities at
participating sites.
Results
Incidence of pleural effusion
DASISION. With a minimum of 5 years of follow up, 73
(28%) patients in DASISION reported drug-related pleural
effusion (Table 1). One case of pleural effusion was not
attributed to dasatinib by the investigator (Grade 2) and
occurred >30 days after the last study dose was given.
Most drug-related pleural effusions were Grade 1 (8%) or
Grade 2 (17%), and no Grade 4 events were reported. The
median duration of all first cases of drug-related pleural
effusion was 4 weeks. The median daily dose of dasatinib
for patients who developed drug-related pleural effusion
was 100 mg, similar to the overall dasatinib-treated popu-
lation.19 
New cases of pleural effusion (any grade) occurred in
8% of patients receiving dasatinib in the first year of the
study, and 6-9% each remaining year up to 5 years, sug-
gesting a steady but continuous risk over time (Table 1).
The proportion of patients with a recurrent (>1) drug-
related pleural effusion (any grade) was 62% (n=45/73).
Of these, 16 patients had 2 separate events, 6 had 3 sepa-
rate events, 4 had 4 separate events, and 19 had ≥5 sepa-
rate events. Twelve patients discontinued due to recurrent
pleural effusion. Of these patients, 9 had ≥3 recurring
events. Dose interruptions and dose reductions due to
pleural effusion occurred in 62% and 41% of patients,
respectively.
034/Dose-optimization. With a minimum follow up of 7
years, drug-related pleural effusion (any grade) occurred in
33% of patients (Table 1). Although the median dose of
dasatinib for patients with drug-related pleural effusion
(any grade) was 100 mg daily (range 0-180 mg), pleural
effusion rates varied across dosing groups in 034/Dose-
optimization, with 28% (n=46/165) of patients experienc-
ing any-grade pleural effusion in the 100 mg QD group
and 35% (n=174/497) in the other groups. The median
duration of first pleural effusion was 4 weeks. The major-
ity of drug-related pleural effusions were Grade 1/2, and
Grade 3/4 drug-related pleural effusions were reported in
48 (7%) patients in the total treated population. Of these,
8 occurred in the 100 mg QD group and 40 in the remain-
ing groups. First occurrences of pleural effusion (any
grade) occurred in 15% of dasatinib-treated patients in the
first year of the study, and in 5-10% per year up to 7 years.
Recurrent (>1) drug-related pleural effusion (any grade)
occurred in 61% (n=134/220). Of these, 54 patients had 2
separate events, 31 had 3 separate events, 16 had 4 sepa-
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Table 2. Hypertension by occurrence of drug-related pleural effusion in dasatinib-treated patients with CML-CP in DASISION and 
034/Dose-optimization. 
Dasatinib-treated patients, n (%) 
DASISION 034/Dose-optimization
(n=258) (n=662)
Patients with baseline hypertension 28 (11) 61 (9)
With PE 13 (46) 24 (39)
Without PE 15 (54) 37 (61)
With anti-hypertensive medication 20 (71) 40 (66)
With PE 9 (45) 18 (45)
Without PE 11 (55) 22 (55)
Without anti-hypertensive medication 8 (29) 21 (34)
With PE 4 (50) 6 (29)
Without PE 4 (50) 15 (71)
Patients without baseline hypertension 230 (89) 601 (91)
With PE 60 (26) 196 (33)
Without PE 170 (74) 405 (67)
CML-CP: chronic myeloid leukemia in chronic phase; PE: pleural effusion.
Table 3. Age by occurrence of drug-related pleural effusion in dasatinib-treated patients with CML-CP in DASISION and 034/Dose-optimization.
Age, years DASISION (n=258) 034/Dose-optimization (n=662)
No PE With PE No PE With PE
(n=185) (n=73) (n=442) (n=220)
Mean (standard deviation) 43 (14) 55 (13) 52 (15) 58 (13)
95% CI (mean) (41-45) (52-58) (50-53) (57-60)
Median (range) 41 (18-84) 56 (24-82) 53 (18-84) 60 (22-84)
95% CI (median) (41-45) (52-58) (50-53) (57-60)
CI: confidence interval; CML-CP: chronic myeloid leukemia in chronic phase; PE: pleural effusion.  
rate events, and 33 had ≥5 separate events. In all
034/Dose-optimization dose groups, discontinuation due
to recurrent pleural effusion occurred in 46 (7%) patients.
The cumulative incidence rate of pleural effusion was
lower in the 100 mg QD group than in dose groups and
increased over time (at 2 years 15% vs. 24%, respectively;
at 7 years 27% vs. 36%, respectively). Similarly, the cumu-
lative incidence rate of Grade 3/4 pleural effusion was
lower in the 100 mg QD group than in the other dose
groups (at 7 years 5% vs. 9%, respectively), and increased
over time (at 2 years 2% vs. 4%, respectively; at 5 years
4% vs. 7%, respectively). Within year 7 of the study, new
cases of pleural effusion occurred in 5% (2/42) of patients
at risk treated with dasatinib 100 mg QD and in 8% (7/91)
of patients at risk in the other treatment arms. The cumu-
lative rates of drug-related pleural effusion over time for
the 100 mg QD arm were 14% at 2 years, 24% at 5 years,
and 28% at 7 years. For the other treatment arms, the
cumulative rates of drug-related pleural effusion over time
were 24% at 2 years, 32% at 5 years, and 35% at 7 years. 
The incidence of pleural effusion was also lower in ima-
tinib-intolerant and imatinib-resistant patients receiving
100 mg QD than in the other dose groups. Pleural effusion
(any grade) was reported in 19% of patients who were
imatinib-intolerant in the 100 mg QD arm and in 43% of
imatinib-intolerant patients in the other dose groups,
while pleural effusion (any grade) was reported in 31% of
imatinib-resistant patients in the 100 mg QD arm and in
35% in the other dose groups. Pleural effusions were man-
aged with dose interruptions in 44% of patients.
Pooled population of patients with Ph+ leukemia. Eleven
dasatinib clinical trials of patients with Ph+ leukemia,
including the DASISION and 034/Dose-optimization tri-
als, were pooled for this analysis to include the largest
number of dasatinib-treated patients possible. Pleural effu-
sion of any grade from any cause occurred in 946 patients
(35%), 553 (34%) with CML-CP and 393 (36%) with
CML-AP/BP or Ph+ ALL. Grade 3/4 pleural effusions were
reported in 223 (8.2%) patients, 119 (7%) with CML-CP,
and 104 (10%) with CML-AP/BP or Ph+ ALL. Deaths due
to pleural effusion were reported in 5 (<1%) patients, all
with CML-AP/BP or Ph+ ALL (4 were not receiving the cur-
rently approved dose of 140 mg QD dasatinib1). Drug-
related pleural effusion of any grade occurred in 538 (33%)
patients with CML-CP and 345 (32%) with CML-AP/BP
or Ph+ ALL (883 [33%] patients total). Grade 3/4 drug-
related pleural effusion episodes were reported in 114
(7%) patients with CML-CP and 93 (9%) patients with
CML-AP/BP or Ph+ ALL (207 [8%] patients in total). One
drug-related death was reported (<1%) in a patient with
CML-AP/BP or Ph+ ALL.
Risk factors for pleural effusion
Based on risk factors for pleural effusion in dasatinib-
treated patients described in literature,9,11-13 retrospective
multivariate analyses were performed to investigate the
association between pleural effusion and baseline hyper-
tension, age, and lymphocytosis in patients treated with
dasatinib, as well as additional variables of interest includ-
ing sex, region, dosing schedule (034/Dose-optimization
only), baseline Euro (Hasford) risk scores (DASISION
only), exposure to interferon alpha (034/Dose-optimiza-
tion only), BCR-ABL1 levels, baseline parameters, major
molecular response (MMR) at 12 months, line of therapy,
duration of prior TKI therapy, and depth of MR at any
time. Average daily dose, prior skin rash, and prior
autoimmune or lung disease were assessed in the DASI-
SION/034/Dose-optimization pooled population only.
DASISION. In DASISION, 28 (11%) patients had hyper-
tension, and 13 of 28 (46%) patients with hypertension
developed drug-related pleural effusion (Table 2). Of the
13 patients who developed pleural effusion, 9 were taking
antihypertensive medications. When the relation between
hypertension and pleural effusion was assessed in a mul-
tivariate analysis, there was no significant association
found (Figure 1A). Pulmonary hypertension was reported
in 14 (5%) dasatinib-treated patients, 9 of whom had pleu-
ral effusion. One patient with pulmonary hypertension
underwent right heart catheterization in order to confirm
pulmonary arterial hypertension (PAH); however, the pro-
cedure did not support a diagnosis of PAH. Twelve of the
14 pulmonary hypertension diagnoses were drug related.19
In DASISION, the correlation between pulmonary hyper-
tension and pleural effusion was not confirmed.
The median age of patients who developed drug-related
pleural effusion in DASISION was 56 years, whereas for
patients who did not develop pleural effusions it was 
41 years (Table 3). Of significance, older age was found to
be a risk factor for developing pleural effusion (odds ratio
[OR] 1.067; 95% confidence interval [CI] 1.041-1.094;
Figure 1A). These results were confirmed using a reduced
model multivariate analysis.
In DASISION, 29 (11%) patients had lymphocytosis at
any time prior to pleural effusion, and 0 patients devel-
oped lymphocytosis after. However, lymphocytosis was
not found to be a significant risk factor for the develop-
ment of pleural effusion by multivariate analysis (Figure
1A). 
Of the patients receiving 100 mg QD dasatinib in the
DASISION trial, 86 (33%) patients had low-risk Euro
scores, 124 (48%) had intermediate-risk Euro scores, and
49 (19%) had high-risk Euro scores.16 Using a reduced
model multivariate analysis, patients with intermediate-
risk Euro scores were not found to be at an increased risk
of developing pleural effusion compared with patients
with low-risk Euro scores. Similarly, no association was
observed between pleural effusion and patients with high-
risk Euro scores compared with patients with low-risk
Euro scores.
The remaining variables investigated via multivariate
analysis were found not to have an association with pleu-
ral effusion (Figure 1A). 
034/Dose-optimization. Similar to DASISION, no signifi-
cant association between pleural effusion and hyperten-
sion was found for patients in 034/Dose-optimization
treated with dasatinib 100 mg QD, the currently approved
dose for CML-CP1 (Figure 1B). Twenty-four of 61 (39%)
patients from any treatment arm with hypertension devel-
oped drug-related pleural effusion (Table 2). Of these 24
patients, 18 were taking antihypertensive medication.
Pulmonary hypertension (any grade) was reported in 3
(2%) patients in the 100 mg QD dose group and in 13
(3%) patients in the other dose groups.23 One patient
(<1%) in the 100 mg QD dose group reported severe drug-
related PAH, confirmed with a right heart catheterization
procedure.23 Similar to DASISION, the association
between pulmonary hypertension and pleural effusion
was not confirmed in these patients.
In 034/Dose-optimization, the median age of all
patients who developed drug-related pleural effusion was
Pleural effusion in dasatinib-treated CML patients
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60 years; patients who did not develop pleural effusion
had a median age of 53 years (Table 3). Advanced age was
found to be a significant risk factor for pleural effusion in
patients treated with 100 mg QD dasatinib in a multivari-
ate model (OR 1.074; 95% CI 1.035-1.114; Figure 1B). In
addition to age, a strong statistical correlation was
observed between the depth of MR and the overall inci-
dence of pleural effusion, for those treated with 100 mg
QD dasatinib (OR 3.851; 95% CI 1.182-12.552) (Figure
1B). Both age and depth of MR were confirmed as risk fac-
tors by a reduced model multivariate analysis.
Lymphocytosis was not found to be associated with the
development of pleural effusion in a multivariate analysis
of patients treated with 100 mg QD dasatinib (Figure 1B);
overall, 17 (10%) patients had lymphocytosis before the
onset of pleural effusion versus 0 after. 
No other associations were found between pleural effu-
sion and the remaining variables analyzed via multivariate
analysis (Figure 1B).
Pooled DASISION and 034/Dose-optimization. To assess
the relation between potential prognostic factors and
pleural effusion in a larger population, patients treated
with 100 mg QD dasatinib from both DASISION (n=258)
and 034/Dose-optimization (n=165) were pooled (n=423),
and a multivariate analysis was performed (Figure 1C). In
this pooled population, patients in MMR (OR 2.482; 95%
CI 1.191-5.174) and MR4.5 (OR 2.756; 95% CI 1.30-5.841)
had a significantly increased risk of developing pleural
effusion compared with patients not in MMR. Increased
age also was found to be a significant risk factor (OR
1.069; 95% CI 1.048-1.091). 
In the pooled DASISION and 034/Dose-optimization
patient population, 40 (9%) patients had a history of lung
disease, and 13 (3%) patients had a history of autoim-
mune disease. When the relationship between pleural
effusion and prior lung disease, autoimmune disease, or
skin rash was assessed using a reduced model multivariate
analysis, no association was found. Average daily dasa-
tinib dose also was not found to be a risk factor using the
reduced model. 
In the reduced multivariate model, imatinib-intolerant
patients receiving second-line dasatinib had a significantly
increased risk of developing pleural effusion compared
with first-line patients (OR 0.232; 95% CI 0.086-0.623).
Efficacy of patients with pleural effusion
DASISION. Of 73 dasatinib-treated patients in the
DASISION trial with drug-related pleural effusion, 97%
achieved CCyR, 82% had MMR, and 51% had MR4.5
(Table 4). These results are comparable to those in patients
who did not have drug-related pleural effusion, and reflec-
tive of the overall responses for the entire study popula-
tion.17 Duration of MMR was 39 months for those with 1
drug-related pleural effusion and 45 months for those with
>1 (Table 4). Five-year progression-free survival (PFS) was
similar for patients with or without drug-related pleural
effusion (Online Supplementary Figure S1A). Of patients
who experienced drug-related pleural effusion events,
5/73 (7%) progressed, whereas 21/185 (11%) patients
who did not experience pleural effusion events pro-
gressed. Overall survival (OS) was similar in patients who
did or did not experience drug-related pleural effusion as
well (Online Supplementary Figure S1B).
Many patients did achieve cytogenetic or molecular
responses prior to the first occurrence of drug-related pleu-
ral effusion, and these responses were often maintained or
improved despite dose modifications required to manage
the effusion (Online Supplementary Table S2). Sixty-five
patients (89% of patients with a drug-related pleural effu-
sion) had CCyR, 35 (48%) had MMR, and 12 (16%) had
MR4.5 prior to experiencing their first pleural effusion
event. Following the first pleural effusion, 55 patients
maintained/improved to CCyR. Similarly, 19 patients
maintained/improved to MMR, and 32 patients main-
tained/improved to MR4.5. One patient went from MMR
to BCR-ABL1 0.1-≤1% following their first pleural effu-
sion event. No patient had BCR-ABL1 >10% or lost any
cytogenetic response after their first event.
034/Dose-optimization. Of 220 dasatinib-treated patients
in 034/Dose-optimization who had drug-related pleural
effusion, 66% achieved CCyR, 53% had MMR, and 18%
had MR4.5 (Table 4). As seen in the DASISION trial, molec-
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Table 4. Efficacy of dasatinib by occurrence of drug-related pleural effusion in dasatinib-treated patients with CML-CP in DASISION and 
034/Dose-optimization. 
Dasatinib-treated patients, n (%)
DASISION* (N=258) 034/Dose-optimization† (N=662)
No PE With PE 1 PE >1 PE Total No PE With PE 1 PE >1 PE Total
(n=185) (n=73) (n=28) (n=45) (n=258) (n=442) (n=220) (n=86) (n=134) (n=662)
Best response to dasatinib‡
MMR 138 60 24 36 198 162 117 37 80 279
(75) (82) (86) (80) (77) (37) (53) (43) (60) (42)
MR4.5 78 37 NA NA 115 57 40 NA NA 97 
(42) (51) (45) (13) (18) (15)
CCyR 155 71 NA NA 226 193 146 NA NA 339
(84) (97) (88) (44) (66) (51)
Median MMR duration, NA NA 39 45 48 NA NA 34 42 43 
months (range) (0-68) (0-70) (0-70) (0-85) (0-84) (0-90)
*Both on-study and follow-up patients are included. †Only on-study patients are included. ‡All responses listed were those obtained at end of study. For DASISION, that was 
60 months, and for 034/Dose-optimization, that was 84 months. CCyR: complete cytogenetic response; CML-CP: chronic myeloid leukemia in chronic phase; MMR: major molecular
response, BCR-ABL1 transcripts ≤0.1% on the International Scale (IS) corresponding to a 3-log reduction from the standardized baseline; MR4.5: BCR-ABL1 transcripts ≤0.0032%
(IS) corresponding to a 4.5-log reduction from the standardized baseline; NA: not applicable; PE: pleural effusion. 
ular responses in the 034/Dose-optimization trial for
patients who had drug-related pleural effusion events 
versus patients who did not were similar, although a trend
showed slightly higher molecular responses for those who
experienced pleural effusions. The duration of MMR was
34 months for those with 1 drug-related pleural effusion,
and 42 months for those with >1 (Table 4). At the end of
the 034/Dose-optimization 7-year study, PFS for dasa-
tinib-treated patients who experienced drug-related pleu-
ral effusion events was similar to PFS for patients who did
not experience effusion events (Online Supplementary
Figure S2A). Among patients who had drug-related pleural
effusion, 93/220 (42%) progressed, compared with
220/442 (50%) patients who did not have pleural effusion
but did progress. Seven-year OS in 034/Dose-optimiza-
tion was similar across patients with and without drug-
related pleural effusion (Online Supplementary Figure S2B).
As seen in DASISION, patients in 034/Dose-optimiza-
tion were able to achieve responses prior to their first
event, and these responses were maintained or improved
following the pleural effusion in some patients (Online
Supplementary Table S3). One hundred and sixteen patients
(53% of patients with a drug-related pleural effusion
evaluable for efficacy endpoints) had CCyR, 66 (30%) had
MMR, and 15 (7%) had MR4.5 prior to experiencing a first
case of pleural effusion. Following the effusion, 55
patients maintained or improved to CCyR and 9 patients
lost CCyR. Changes in the depth of molecular response
were also similar: 55 patients maintained/improved to
MMR, and 31 patients maintained/improved to MR4.5.
Three patients went from MMR to BCR-ABL1 0.1-≤1%
following their first pleural effusion event. Of these
patients, all had BCR-ABL1 >0.1% after their first event.
Two patients in 034/Dose-optimization were excluded
from the efficacy analysis because the date of onset of
pleural effusion was not captured.
Discussion
Pleural effusion has been reported in dasatinib-treated
patients at any time during the course of treatment,
though the severity is generally mild to moderate. Grade
1 effusions are often asymptomatic and may not have
been picked up in the absence of routine chest X-rays
(only required in the DASISION trial), potentially reduc-
ing the incidence of clinically significant effusions in this
patient population. However, we cannot comment that
Grade 1 pleural effusions would not progress with time.
The risk of pleural effusion remains even after long-term
dasatinib treatment in effusion-naive patients; thus, main-
taining awareness of the risk is important.
As fluid retention events have been reported with most
BCR-ABL1-targeted TKIs, it is tempting to attribute the
occurrence of pleural effusion to a class effect on fluid
overload. However, an immune-mediated mechanism is
more likely for dasatinib-related pleural effusion, as exu-
date containing high lymphocyte counts (predominantly
natural killer cells) and chyle accumulate have been report-
ed in pleural fluids and tissue from patients on dasa-
tinib.15,33,34 Pleural effusion developed slightly more often in
patients with lymphocytosis than in patients without
lymphocytosis (33% with lymphocytosis vs. 26% with-
out lymphocytosis) in the DASISION trial, although this
difference was not statistically significant.35 We found that
lymphocytosis occurred during therapy, which appears to
represent a risk factor for pleural effusion because it pre-
ceded pleural effusion events.
Through multivariate analyses, we determined that
race, sex, region, exposure to interferon, BCR-ABL1 levels
at 3 months, lymphocytosis, colitis, history of autoim-
mune disease, history of lung disease, history of skin rash,
baseline smoking history, MMR at 12 months, average
daily dose, line of therapy, baseline Euro risk scores, and
duration of prior TKI therapy were not associated with an
increased risk of pleural effusion. Other risk factors for
pleural effusion previously described include advanced
disease, heart disease, and hypercholesterolemia.10,12-14 It is
difficult to analyze the association between the incidence
of pleural effusion and the depth of molecular response
achieved without correcting for the time of dasatinib
exposure, given that most patients achieving deep molec-
ular responses are typically on dasatinib longer and would
therefore be expected to have a greater risk of developing
pleural effusion. To address this, we evaluated MMR at 
12 months as a potential risk factor; however, no associa-
tion was observed. We found second-line patients with
previous intolerance of imatinib to be at an increased risk
of developing pleural effusion compared with first-line
patients, although no association was observed for sec-
ond-line imatinib-resistant patients. Finally, although effu-
sions can develop in adults at any age, we determined that
advanced age was the only significant patient risk factor
for pleural effusion, particularly in those treated with 
100 mg/day of dasatinib. Additional potential risk factors,
such as a history of hypertension, can develop during
treatment with dasatinib, and should be considered when
evaluating individual patients, though the association
between pleural effusion and hypertension was not sub-
stantiated in this analysis. 
Dasatinib dose, as a potential risk factor for pleural effu-
sion, is of special interest. Wang et al. noted that pleural
effusion was associated with trough drug concentrations,
indicating that dasatinib pharmacokinetics may play a role
in the development of pleural effusion.13 We did not find
dasatinib dose to be a risk factor for the development of
pleural effusion in the pooled population of patients ini-
tially treated with 100 mg QD dasatinib. However, since
patients with advanced disease in the pooled population
of dasatinib-treated patients with Ph+ leukemia described
here were treated with higher doses of dasatinib (up to
240 mg daily) than patients with CML-CP, dasatinib dose
may still be associated with the increased rate of 
Grade 3/4 pleural effusions observed. Also, we reported
that pleural effusion (any grade) was observed in a lower
percentage of patients in the 100 mg QD arm versus the
other dose groups in 034/Dose-optimization. A retrospec-
tive study evaluating the toxicity-guided administration of
a reduced-dose dasatinib regimen in similar imatinib-resis-
tant/intolerant patients revealed that on/off treatment sig-
nificantly reduced pleural effusions.36 Furthermore, recent
sub-analyses of DASISION revealed that dose reductions
for adverse events, including pleural effusion, did not
affect dasatinib efficacy,37,38 suggesting that it may be pos-
sible to administer lower doses to populations at higher
risk for pleural effusion development. Moreover, we
found that the achievement of MMR and MR4.5 was found
to be correlated with a higher risk of developing pleural
effusion. This may be because patients without MMR
may have discontinued dasatinib treatment earlier than
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those with a response. This supports a hypothesis that
pleural effusion may be a marker for longevity of treat-
ment: As patients do well on dasatinib and remain on
treatment longer, they may be more likely to develop a
pleural effusion.  Further investigation into the relation
between duration of treatment and pleural effusion is war-
ranted.
Clinical data on molecular responses for patients who
experienced pleural effusions during treatment with dasa-
tinib are limited, though our observations indicate that
patients who experienced pleural effusions while on dasa-
tinib had similar responses to treatment as those who did
not develop pleural effusion. A retrospective study exam-
ining dasatinib-related pleural effusion in CML patients
across 21 hematologic centers in Italy revealed that at the
time of the first effusion, 28.6% were in MMR and 37.8%
were in MR4.5.39 
In summary, pleural effusion is an adverse event seen
disproportionately in patients treated with dasatinib;
however, the management of pleural effusion by dose
reductions does not negatively affect the response rate to
dasatinib. Advanced age and longevity of treatment were
found to be predictive risk factors for the development of
pleural effusion.
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